Table 4.

Semiquantitative analysis of antibody response to angiogenic cytokines in vaccinated patients with recurrent malignant glioma

Patient numberL1DEL-1Ang1Ang2HGFPDGFVEGF-AaVEGF-APGRN
2+++++
3++++++++++
4+++++++++++++
5++++++++++++++++++
6+++++
8++++
9++++
10+++++++++
11+++++++++
  • NOTE: +, two and one half to five-fold increases; ++ five- to six-fold increases; +++, eight- and greater fold increases.

  • Patients 2, 3, 4, 5, and 11 received bevacizumab at weeks 7, 6, 10, 10, and 10, respectively.

  • aVEGF-A before bevacizumab. Patients 2 to 5 had blood sampled after bevacizumab administration.